Determination of diclofenac sodium by capillary zone electrophoresis with electrochemical detection

Validation of an HPLC Method for the Determination of Diclofenac Diethylamine and Three of Its Impurities in a Gel Pharmaceutical Form

BACKGROUND

Monitoring impurities in drug products is a principal requirement of pharmaceutical regulatory authorities all over the world to ensure drug safety. For this reason, there is a great need for analytical QC of dugs products.

OBJECTIVE

In this study, a simple, efficient, and direct HPLC method was developed for the determination of three impurities of diclofenac.

METHODS

The HPLC method was developed using a mobile phase which consisted of an HPLC grade mixture, acetonitrile-0.01M phosphoric acid adjusted to pH 2.3 (1 + 3, by volume).

RESULTS

The separation was performed in 15 min. The calibration curves of the three impurities were linear; the correlation coefficients were 0.999 at concentrations of 0.00015-0.003 µg/mL.

CONCLUSION

The validation of this method shows that it meets all validation criteria. This shows the reliability of this method for the routine control of diclofenac impurities.

HIGHLIGHTS

The validation of a robust HPLC method for the determination of diclofenac impurities is of great importance for the pharmaceutical industry to control its products.

Functionalized Multi-Walled Carbon Nanotube–Based Aptasensors for Diclofenac Detection

Driven by the increasing concern about the risk of diclofenac (DCF) residues as water pollutants in the aqueous environment and the growing need for its trace determination, a simple but sensitive electrochemical aptasensor for the trace detection of DCF was developed. To construct the aptasensor, the amine-terminated DCF aptamer was covalently immobilized on the surface of the carboxylic acid–functionalized multi-walled carbon nanotube (f-MWCNT)–modified glassy carbon electrode (GCE) through EDC/NHS chemistry. The f-MWCNTs provide a reliable matrix for aptamer immobilization with high grafting density, while the aptamer serves as a biorecognition probe for DCF. The obtained aptasensor was incubated with DCF solutions at different concentrations and was then investigated by electrochemical impedance spectroscopy (EIS). It displays two linear ranges of concentration for DCF detection, from 250 fM to 1pM and from 1 pM to 500 nM with an extremely low detection limit of 162 fM. Also, the developed biosensor shows great reproducibility, acceptable stability, and reliable selectivity. Therefore, it offers a simple but effective aptasensor construction strategy for trace detection of DCF and is anticipated to show great potential for environmental applications.

Electrochemical Determination of Diclofenac by Using ZIF-67/g-C3N4 Modified Electrode

A facial differential pulse voltammetric procedure using a glassy carbon electrode modified with zeolite imidazolate framework-67/graphitic carbon nitride (ZIF-67/g-C3N4) for the diclofenac (DCF) determination is demonstrated. ZIF-67/g-C3N4 with different mass ratios of the components was synthesized in a self-assembly process. The obtained materials were characterized by using X-ray diffraction, scanning electron microscopy (SEM), EDX-mapping, and nitrogen adsorption/desorption isotherms. The peak current varies linearly with the DCF concentration in the range of 0.2–2.2 μmol·L−1 and has a detection limit of 0.071 μmol·L−1. The modified electrode exhibits acceptable repeatability, reproducibility, and selectivity towards DCF. The proposed electrode allows determining DCF in human urine without pretreatment, and the results are comparable with those determined with HPLC.

Au nanoparticle plasmon-enhanced electrochemiluminescence aptasensor based on the 1D/2D PTCA/CoP for diclofenac assay

The combination of localized surface plasmon resonance (LSPR) and electrochemiluminescence (ECL) can be an effective way to amplify the signal intensity. In this work, an ECL aptasensor with 3,4,9,10-perylenetetracarboxylic acid-decorated cobalt phosphate (denoted as PTCA/CoP) as the ECL emitter and Au nanoparticles (NPs) as plasma was proposed for diclofenac assay. The prepared PTCA/CoP with special 1D/2D structure exhibited good ability and excellent ECL performance. The diclofenac aptamer acted as a bridge to link the PTCA/CoP and Au NPs; thus, the ECL performance of PTCA/CoP was greatly improved due to the plasma effect of Au NPs. Besides, it was found that the ECL signal of the aptasensor was obviously quenched by the introduction of diclofenac, which might be due to the transformation from the LSPR process to the resonance energy transform (RET) process. Under optimal conditions, the difference of ECL intensity was negatively correlated with the concentration of diclofenac in the range 0.1 pM to 10 μM with a low detection limit of 0.072 pM at the potential of -1.8 V vs. Ag/AgCl (S/N = 3). The aptasensor was proved to be suitable for the detection of diclofenac in real samples, suggesting its great practicability.

A Box-Behnken Optimized Methodology for the Quantification of Diclofenac using a Carbon Paste-Multiwalled Carbon Nanotubes Electrode

Background:

Diclofenac is a widely used nonsteroidal anti-inflammatory drug. Recent studies have shown that frequent consumption of this drug in high concentrations can cause heart diseases, so strict control of diclofenac’s quantity in commercial drugs is necessary. This paper presents the development of an optimized voltammetric methodology for the quantification of diclofenac, which offers some advantages over other electrochemical and accepted methods.

Objective:

Optimize with a Box-Behnken design the differential pulse voltammetry parameters towards the quantification of diclofenac in pharmaceutical samples.

Methods:

Diclofenac behavior in the working electrode was evaluated by cyclic voltammetry, in order to stablish the best conditions for diclofenac’s quantification. A Box-Behnken design was then used to optimize the differential pulse voltammetry parameters and stablish the analytical behavior of the proposed methodology. Commercial tablets were prepared for analysis according to the Pharmacopeia, the DPV optimized methodology was used to quantify diclofenac in the samples, and the results were statistically compared with those obtained with the official methodology.

Results:

After optimization, the analytical parameters found were: correlation coefficient of 0.998, detection limit of 0.001 µM, quantification limit of 0.0033 µM and sensitivity of 0.299 µA.µM-1. The statistical analysis showed there were no significant differences between the results obtained with the proposed methodology and those obtained with the official methodology.

Conclusion:

The statistical analysis showed that the proposed methodology is as reliable as the official spectrophotometric one for the quantification of diclofenac in commercial drugs, with very competitive analytical parameters, and even better to others found with more complex electrodes.

A new diclofenac molecularly imprinted electrochemical sensor based upon a polyaniline/reduced graphene oxide nano-composite

A diclofenac (DCF)-imprinted polymer, composed of polyaniline, reduced graphene oxide (rGO) and triphenylamine, as cross linker, was synthetized. This composite was identified by using SEM and FT-IR techniques. The prepared DCF-imprinted polymer (MIP) was used for modification of carbon paste electrodes (CPEs) to fabricate a selective DCF electrochemical sensor. Electrochemical behavior of DCF on the investigated sensor and the optimization of the parameters affecting the DCF determination were screened by cyclic voltammetry (CV). The cyclic voltammogram of DCF showed an anodic peak current at about 0.5 V (vs. SCE). The calibration curve for DCF determination was obtained by applying the investigated sensor as working electrode in differential pulse voltammetry (DPV). A linear increase in the anodic peak current was observed in the range 5-80 mg L^-1 of DCF. The corresponding limit of detection was calculated to be 1.1 mg L^-1. The relative standard deviations of the inter- and intra-day analysis of DCF presented by the method were found to be as 2.43% and 2.47%, respectively. The selectivity of the investigated sensor was evaluated by its use for determination of DCF in the binary solutions containing DCF/glucose, DCF/urea and DCF/ascorbic acid. It was shown that the fabricated electrode can be successfully used for analysis of DCF in pharmaceutical and urine samples.

Encapsulating genetically modified Saccharomyces cerevisiae cells in a flow-through device towards the detection of diclofenac in wastewater

Recently it has been proposed to use sensors based on genetically engineered reporter cells to perform continuous online water monitoring. Here we describe the design, assembly and performance of a novel flow-through device with immobilized genetically modified yeast cells that produce a fluorescent protein upon stimulation with diclofenac whose intensity is then detected by fluorescence microscopy. Although other devices employing immobilized cells for the detection of various analytes have already been described before, as novelty our system allows safe enclosure of the sensor cells, and thus, to obtain fluorescent signals that are not falsified by a loss of cells. Furthermore, the yeast cells are prevented from being released into the environment. Despite the safe containment, the immobilized reporter cells are accessible to nutrients and analytes. They thus have both the ability to grow and respond to the analyte. Both in cell culture medium and standardized synthetic wastewater, we are able to differentiate between diclofenac concentrations in a range from 10 to 100 μM. As particularly interesting feature, we show that only the biologically active fraction of diclofenac is detected. Nowadays, contamination of wastewater with diclofenac and other pharmaceutical residues is becoming a severe problem. Our investigations may pave the way for an easy-to-use and cost-efficient wastewater monitoring method.

A comprehensive strategy in the development of a cyclodextrin-modified microemulsion electrokinetic chromatographic method for the assay of diclofenac and its impurities: Mixture-process variable experiments and quality by design

A comprehensive strategy involving the use of mixture-process variable (MPV) approach and Quality by Design principles has been applied in the development of a capillary electrophoresis method for the simultaneous determination of the anti-inflammatory drug diclofenac and its five related substances. The selected operative mode consisted in microemulsion electrokinetic chromatography with the addition of methyl-β-cyclodextrin. The critical process parameters included both the mixture components (MCs) of the microemulsion and the process variables (PVs). The MPV approach allowed the simultaneous investigation of the effects of MCs and PVs on the critical resolution between diclofenac and its 2-deschloro-2-bromo analogue and on analysis time. MPV experiments were used both in the screening phase and in the Response Surface Methodology, making it possible to draw MCs and PVs contour plots and to find important interactions between MCs and PVs. Robustness testing was carried out by MPV experiments and validation was performed following International Conference on Harmonisation guidelines. The method was applied to a real sample of diclofenac gastro-resistant tablets.

A novel stability-indicating UPLC method development and validation for the determination of seven impurities in various diclofenac pharmaceutical dosage forms

An innovative simple, fast, precise and accurate ultra-high performance liquid chromatography (UPLC) method was developed for the determination of diclofenac (Dic) along with its impurities including the new dimer impurity in various pharmaceutical dosage forms. An Acquity HSS T3 (C18, 100×2.1mm, 1.8μm) column in gradient mode was used with mobile phase comprising of phosphoric acid, which has a pH value of 2.3 and methanol. The flow rate and the injection volume were set at 0.35ml·min(-1) and 1μl, respectively, and the UV detection was carried out at 254nm by using photodiode array detector. Dic was subjected to stress conditions from acid, base, hydrolytic, thermal, oxidative and photolytic degradation. The new developed method was successfully validated in accordance to the International Conference on Harmonization (ICH) guidelines with respect to specificity, limit of detection, limit of quantitation, precision, linearity, accuracy and robustness. The degradation products were well resolved from main peak and its seven impurities, proving the specificity power of the method. The method showed good linearity with consistent recoveries for Dic content and its impurities. The relative percentage of standard deviation obtained for the repeatability and intermediate precision experiments was less than 3% and LOQ was less than 0.5μg·ml(-1) for all compounds. The new proposed method was found to be accurate, precise, specific, linear and robust. In addition, the method was successfully applied for the assay determination of Dic and its impurities in the several pharmaceutical dosage forms.

Differential pulse voltammetric determination of diclofenac in pharmaceutical preparations and human serum

<p>This article describes a differential pulse voltammetric (DPV) method for the determination of diclofenac in pharmaceutical preparations and human serum. The proposed method was based on electro-oxidation of diclofenac at platinum electrode in 0.1 M TBAClO₄/acetonitrile solution. The well-defined two oxidation peaks were observed at 0.87 and 1.27 V, respectively. Calibration curves that obtained by using current values measured for second peak were linear over the concentration range of 1.5-17.5 μg mL^-1and 2-20 μg mL^-1 in supporting electrolyte and serum, respectively. Precision and accuracy were also checked in all media. Intra- and inter-day precision values for diclofenac were less than 3.87, and accuracy (relative error) was better than 4.12%. The method developed in this study is accurate, precise and can be easily applied to Diclomec, Dicloflam and Voltaren tablets as pharmaceutical preparation. In addition, the proposed technique was successfully applied to spiked human serum samples. No electro-active interferences from the endogenous substances were found in human serum.</p>

Determination of diclofenac in pharmaceutical preparations by voltammetry and gas chromatography methods

Rapid, sensitive and specific methods were developed for the determination of diclofenac in pharmaceutical preparations by linear sweep voltammetry (LSV) and gas chromatography (GC) with mass spectrometry (MS) detection. The linearity was established over the concentration range of 5–35 μg/mL for LSV and 0.25–5 μg/mL for GC–MS method. The intra- and inter-day relative standard deviation (RSD) was less than 4.39% and 4.62% for LSV and GC–MS, respectively. Limits of quantification (LOQ) were determined as 4.8 and 0.15 μg/mL for LSV and GC–MS, respectively. No interference was found from tablet excipients at the selected assay conditions. The methods were applied for the quality control of commercial diclofenac dosage forms to quantify the drug and to check the formulation content uniformity.

Diclofenac on boron-doped diamond electrode: from electroanalytical determination to prediction of the electrooxidation mechanism with HPLC-ESI/HRMS and computational simulations

Using square-wave voltammetry coupled to the boron-doped diamond electrode (BDDE), it was possible to develop an analytical methodology for identification and quantification of diclofenac (DCL) in tablets and synthetic urine. The electroanalytical procedure was validated, with results being statistically equal to those obtained by chromatographic standard method, showing linear range of 4.94 × 10(-7) to 4.43 × 10(-6) mol L(-1), detection limit of 1.15 × 10(-7) mol L(-1), quantification limit of 3.85 × 10(-7) mol L(-1), repeatability of 3.05% (n = 10), and reproducibility of 1.27% (n = 5). The association of electrochemical techniques with UV-vis spectroscopy, computational simulations and HPLC-ESI/HRMS led us to conclude that the electrooxidation of DCL on the BDDE involved two electrons and two protons, where the products are colorful and easily hydrolyzable dimers. Density functional theory calculations allowed to evaluate the stability of dimers A, B, and C, suggesting dimer C was more stable than the other two proposed structures, ca. 4 kcal mol(-1). The comparison of the dimers stabilities with the stabilities of the molecular ions observed in the MS, the compounds that showed retention time (RT) of 15.53, 21.44, and 22.39 min were identified as the dimers B, C, and A, respectively. Corroborating the observed chromatographic profile, dimer B had a dipole moment almost twice higher than that of dimers A and C. As expected, dimer B has really shorter RT than dimers A and C. The majority dimer was the A (71%) and the C (19.8%) should be the minority dimer. However, the minority was the dimer B, which was formed in the proportion of 9.2%. This inversion between the formation proportion of dimer B and dimer C can be explained by preferential conformation of the intermediaries (cation-radicals) on the surface.

Flow injection determination of diclofenac sodium based on its sensitizing effect on the chemiluminescent reaction of acidic potassium permanganate-formaldehyde

A sensitive and simple chemiluminescent (CL) method for the determination of diclofenac sodium has been developed by combining the flow injection technique and its sensitizing effect on the weak CL reaction between formaldehyde and acidic potassium permanganate. A calibration curve is constructed for diclofenac sodium under optimized experimental parameters over the range 0.040-5.0 µg/mL and the limit of detection is 0.020 µg/mL (3σ). The inter-assay relative standard deviation for 0.040 µg/mL diclofenac sodium (n = 11) is 2.0%. This method is rapid, sensitive, simple, and shows good selectivity and reproducibility. The proposed method has been successfully applied to the determination of the studied diclofenac sodium in pharmaceutical preparations with satisfactory results. Furthermore, the possible mechanism for the CL reaction has been discussed in detail on the basis of UV and CL spectra.

Rapid determination of diclofenac in pharmaceutical formulations by capillary zone electrophoresis

Capillary electrophoresis is competitive to HPLC and other chromatographic methods, predominantly when charged analytes have to be separated. The time of analysis can be reduced by the use of very short capillaries applying a high voltage. In most instruments which are commercially available the so-called 'short end' of the capillary can be used for separation, leading to very rapid separations. In this contribution we want to demonstrate this approach by using Diclofenac Sodium as an analyte.

Determination of diclofenac on a dysprosium nanowire- modified carbon paste electrode accomplished in a flow injection system by advanced filtering

A new detection technique called Fast Fourier Transform Square-Wave Voltammetry (FFT SWV) is based on measurements of electrode admittance as a function of potential. The response of the detector (microelectrode), which is generated by a redox processes, is fast, which makes the method suitable for most applications involving flowing electrolytes. The carbon paste electrode was modified by nanostructures to improve sensitivity. Synthesized dysprosium nanowires provide a more effective nanotube-like surface [1-4] so they are good candidates for use as a modifier for electrochemical reactions. The redox properties of diclofenac were used for its determination in human serum and urine samples. The support electrolyte that provided a more defined and intense peak current for diclofenac determination was a 0.05 mol L(-1) acetate buffer pH = 4.0. The drug presented an irreversible oxidation peak at 850 mV vs. Ag/AgCl on a modified nanowire carbon paste electrode which produced high current and reduced the oxidation potential by about 100 mV. Furthermore, the signal-to-noise ratio was significantly increased by application of a discrete Fast Fourier Transform (FFT) method, background subtraction and two-dimensional integration of the electrode response over a selected potential range and time window. To obtain the much sensivity the effective parameters such as frequency, amplitude and pH was optimized. As a result, C(DL) of 2.0 × 10(-9) M and an LOQ of 5.0 × 10(-9) M were found for the determination for diclofenac. A good recovery was obtained for assay spiked urine samples and a good quantification of diclofenac was achieved in a commercial formulation.